Don't be a fool, invest in JOOL, its a gem, get it. Apparently some investors did, shining up JOOL Health with $4.5 million in capital, apparently, as best I can tell from the gibberish in the press release, for something that has to do with digital and patient engagement.
Express Scripts is buying EviCore for $3.6 billion. The purchase suggests that ESI recognizes that the PBM business is losing steam and facing price pressures and a move to broader care management capabilities may provide better future returns.
Trillian Health apparently intents to acquire a trillion companies, as it has made three recent acquisitions to bolster its health data and analytics business, including Expression Health Analytics, Aegis Health, and Clariture Health.
According to an AHRQ Statistical Brief, 35% of child visits to a physician were paid for by Medicaid and the average payment per visit by Medicaid was $88 less than that paid by private insurance. Hard-to-imagine that many physicians will continue to serve children covered by Medicaid with kind of gap.
Research at JAMA Internal Medicine suggests that doctors who have a financial interest in imaging equipment and a history of low-value imaging, are most likely to do additional low-value imaging for low back and head pain.
According to research published in the Journal of the American Medical Informatics Association, comparing online quality ratings of 78 doctors to more objective quality performance measures indicates that online reviews aren't worth much. This is likely because consumers rate quality on much they like a physician and other intangibles.
Patients may be wise, but we will see about investors, as PatientWisdom grabs and undisclosed amount of funding for its app that lets patients share health care stories. Ahhh, isn't that cute.
HealthSplash, a health care patient communication and scheduling firm, is acquiring DMERX, which does compliance documentation, primarily for the DME segment.
Contrary to the most commonly cited cost, a new study at JAMA Internal Medicine finds that the cost of developing a cancer drug is around $650 million and that companies typically fully recover that cost within a couple of years after approval.
Call9, which connects patients to on-demand emergency physicians and currently is used by skilled nursing facilities, has dialed up investors for a fresh $24 million in capital.
98point6 raises a hot $19.5 million from feverish investors. I am not sure what it does but the geniuses who wrote the press release say the company has an "audacious vision". It uses "deep technology" (on the ocean floor?) to do something related to continuity of care at a "massively lower cost than anything in the market today" (I didn't know cost had mass.) It is not a good sign when you can't tell in the first sentence or two of a press release what a company actually does. These investors are truly delirious.
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at khroche@healthy-skeptic.com.
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at khroche@healthy-skeptic.com.